Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide

European Journal of Immunology

Volumn 37, Issue 5, 2007, Pages 1313-1322

  Kollnberger, Simon ^a   Chan, Antoni ^a   Sun, Mei Yi ^a   Chen, Li Ye ^a   Wright, Cynthia ^a   di Gleria, Kati ^a   McMichael, Andrew ^a   Bowness, Paul ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

Author keywords

HLA B27; KIR; LILR; Peptide

Indexed keywords

AMINO ACID DERIVATIVE; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA B27 ANTIGEN; HLA B57 ANTIGEN; HLA B7 ANTIGEN; HOMODIMER; IMMUNOGLOBULIN RECEPTOR; PEPTIDE DERIVATIVE; TETRAMER;

ANIMAL CELL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENETIC TRANSFECTION; HEAVY CHAIN; INHIBITION KINETICS; KILLER CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS; SPONDYLOSIS;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; BLOTTING, WESTERN; DIMERIZATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EPITOPES; FLOW CYTOMETRY; HLA-B27 ANTIGEN; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; PEPTIDES; RECEPTORS, IMMUNOLOGIC; SPONDYLARTHRITIS; T-LYMPHOCYTES; TRANSFECTION;

EID: 34250342548     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200635997     Document Type: Article

References (39)

1. Bowness, P., Allen, R. L. and McMichael, A. J., Identification of T cell receptor recognition residues for a viral peptide presented by HLA B27. Eur. J. Immunol. 1994. 24: 2357-2363.
2. Lopez de Castro, J. A., The pathogenetic role of HLA-B27 in chronic arthritis. Curr. Opin. Immunol. 1998. 10: 59-66.
3. Colbert, R. A., The immunobiology of HLA-B27: Variations on a theme. Curr. Mol. Med. 2004. 4: 21-30.
4. Allen, R. L., O'Callaghan, C. A., McMichael, A. J. and Bowness, P., Cutting Edge: HLA-B27 can form a novel beta 2-microglobulin-ftee heavy chain homodimer structure. J. Immunol. 1999. 162: 5045-5048.
5. Kollnberger, S., Bird, L. A., Roddis, M., Hacquard-Bouder, C., Kubagawa, H., Bodmer, H. C., Breban, M. et al., HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. J. Immunol. 2004. 173: 1699-1710.
6. Bird, L. A., Peh, C. A., Kollnberger, S., Elliott, T., McMichael, A. J. and Bowness, P., Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. Eur. J. Immunol. 2003. 33: 748-759.
7. Kollnberger, S., Bird, L., Sun, M. Y., Retiere, C., Braud, V. M., McMichael, A. and Bowness, P., Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum. 2002. 46: 2972-2982.
8. Bowness, P., HLA B27 in health and disease: A double-edged sword? Rheumatology 2002. 41: 857-868.
9. Lanier, L. L., NK cell receptors. Annu. Rev. Immunol. 1998. 16: 359-393.
10. Colonna, M., Samaridis, J., Cella, M., Angman, L., Allen, R. L., O'Callaghan, C. A., Dunbar, R. et al., Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J. Immunol. 1998. 160: 3096-3100.
11. Colonna, M., Nakajima, H. and Cella, M., Inhibitory and activating receptors involved in immune surveillance by human NK and myeloid cells. J. Leukoc. Biol. 1999. 66: 718-722.
12. Peruzzi, M., Wagtmann, N. and Long, E. O., A p70 killer cell inhibitory receptor specific for several HLA-B allotypes discriminates among peptides bound to HLA-B*2705. J. Exp. Med. 1996. 184: 1585-1590.
13. Malnati, M. S., Peruzzi, M., Parker, K. C., Biddison, W. E., Ciccone, E., Moretta, A. and Long, E. O., Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 1995. 267: 1016-1018.
14. Colonna, M., Navarro, F., Bellon, T., Llano, M., Garcia, P., Samaridis, J., Angman, L., Cella, M. and Lopez-Botet, M., A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 1997. 186: 1809-1818.
15. Willcox, B. E., Thomas, L. M., Chapman, T. L., Heikema, A. P., West, A. P., Jr. and Bjorkman, P. J., Crystal structure of LIR-2 (ILT4) at 1.8 Å: Differences from LIR-1 (ILT2) in regions implicated in the binding of the human cytomegalovirus class I MHC homolog UL18. BMC Struct. Biol. 2002. 2: 1-9.
16. Allen, R. L., Raine, T., Haude, A., Trowsdale, J. and Wilson, M. J., Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J. Immunol. 2001. 167: 5543-5547.
17. Dohring, C., Scheidegger, D., Samaridis, J., Cella, M. and Colonna, M., A human killer inhibitory receptor specific for HLA-A1,2. J. Immunol. 1996. 156: 3098-3101.
18. Hansasuta, P., Dong, T., Thananchai, H., Weekes, M., Willberg, C., Aldemir, H., Rowland-Jones, S. and Braud, V. M., Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 2004. 34: 1673-1679.
19. Chan, A. T., Kollnberger, S., Wedderburn, L. R. and Bowness, P., Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum. 2005. 52: 3586-3595.
20. Kuon, W., Kuhne, M., Busch, D. H., Atagunduz, P., Seipel, M., Wu, P., Morawietz, L. et al., Identification of novel human aggrecan T cell epitopes in HLA-B27 transgenic mice associated with spondyloarthropathy. J. Immunol. 2004. 173: 4859-4866.
21. Ringrose, J. H., Muijsers, A. O., Pannekoek, Y., Yard, B. A., Boog, C. J., van Alphen, L., Dankert, J. and Feltkamp, T. E., Influence of infection of cells with bacteria associated with reactive arthritis on the peptide repertoire presented by HLA-B27. J. Med. Microbiol. 2001. 50: 385-389.
22. Frauendorf, E., von Goessel, H., May, E. and Marker-Hermann, E., HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides. Clin. Exp. Immunol. 2003. 134: 351-359.
23. Ramos, M., Alvarez, I., Sesma, L., Logean, A., Rognan, D. and Lopez de Castro, J. A., Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J. Biol. Chem. 2002. 277: 37573-37581.
24. Fiorillo, M. T., Maragno, M., Butler, R., Dupuis, M. L. and Sorrentino, R., CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. J. Clin. Invet. 2000. 106: 47-53.
25. Brooks, J. M., Murray, R. J., Thomas, W. A., Kurilla, M. G. and Rickinson, A. B., Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J. Exp. Med. 1993. 178: 879-887.
26. Zweerink, H. J., Gammon, M. C., Utz, U., Sauma, S. Y., Harrer, T., Hawkins, J. C., Johnson, R. P. et al., Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J. Immunol. 1993. 150: 1763-1771.
27. Nixon, D. F., Townsend, A. R., Elvin, J. G., Rizza, C. R., Gallwey, J. and McMichael, A. J., HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 1988. 336: 484-487.
28. Boisgerault, F., Mounier, J., Tieng, V., Stolzenberg, M. C., Khalil-Daher, I., Schmid, M., Sansonetti, P. et al., Alteration of HLA-B27 peptide presentation after infection of transfected routine L cells by Shigella flexneri. Infect. Immun. 1998. 66: 4484-4490.
29. Kuon, W. and Sieper, J., Identification of HLA-B27-restricted peptides in reactive arthritis and other spondyloarthropathies: Computer algorithms and fluorescent activated cell sorting analysis as tools for hunting of HLA-B27-restricted chlamydial and autologous crossreactive peptides involved in reactive arthritis and ankylosing spondylitis. Rheum. Dis. Clin. North Am. 2003. 29: 595-611.
30. Stewart-Jones, G. B., di Gleria, K., Kollnberger, S., McMichael, A. J., Jones, E. Y. and Bowness, P., Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705. Eur. J. Immunol. 2005. 35: 341-351.
31. Hillig, R. C., Hulsmeyer, M., Saenger, W., Welfle, K., Misselwitz, R., Welfle, H., Kozerski, C., Volz, A. et al., Thermodynamic and structural analysis of peptide- and allele-dependent properties of two HLA-B27 subtypes exhibiting differential disease association. J. Biol. Chem. 2004. 279: 652-663.
32. Carr, W. H., Pando, M. J. and Parham, P., KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J. Immunol. 2005. 175: 5222-5229.
33. Stewart, C. A., Laugier-Anfossi, F., Vely, F., Saulquin, X., Riedmuller, J., Tisserant, A., Gauthier, L. et al., Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc. Natl. Acad. Sci. USA 2005. 102: 13224-13229.
34. Mandelboim, O., Wilson, S. B., Vales-Gomez, M., Reyburn, H. T. and Strominger, J. L., Self and viral peptides can initiate lysis by autologous natural killer cells. Proc. Natl. Acad. Sci. USA 1997. 94: 4604-4609.
35. + T cells. Nat. Immunol. 2001. 2: 430-435.
36. Bowness, P., Zaccai, N., Bird, L. and Jones, E. Y., HLA-B27 and disease pathogenesis: New structural and functional insights. Expert Rev. Mol. Med. 1999. 1999: 1-10.
37. Shiroishi, M., Kuroki, K., Ose, T., Rasubala, L., Arase, H., Tsumoto, K., Kumagai, I. et al., Efficient leukocyte Ig-like receptor signalling and crystal structure of disulfide-linked HLA-G dimer. J. Biol. Chem.. 281: 10439-10437.
38. Allan, D. S., Colonna, M., Lanier, L. L., Churakova, T. D., Abrams, J. S., Ellis, S. A., McMichael, A. J. and Braud, V. M., Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. J. Exp. Med. 1999. 189: 1149-1156.
39. + NK cells by HLA-B7 variants and target cells. J. Immunol. 1998. 160: 1573-1580.